Product Description
Adalimumab injection is used to treat the symptoms and prevent the progression of active rheumatoid arthritis and ankylosing spondylitis. It is used in children 2 years of age and older for juvenile idiopathic arthritis.
Mechanisms of Action: TNF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hidradenitis | Colitis | Arthritis, Juvenile | Arthritis, Psoriatic | Arthritis, Rheumatoid | Spondylitis, Ankylosing | Uveitis | Hidradenitis Suppurativa | Psoriasis | Colitis, Ulcerative | Crohn Disease | Arthritis, Infectious | Spondylitis | Arthritis | Oncology Unspecified | Panuveitis | Uveitis, Intermediate | Uveitis, Posterior
Known Adverse Events: Headache | Sinusitis
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Bulgaria, Canada, China, Czech Republic, Estonia, France, Georgia, Germany, Italy, Japan, Latvia, Mexico, Monaco, Netherlands, New Zealand, Poland, Puerto Rico, Russia, Slovakia, Spain, Switzerland, Taiwan, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 27
Highest Development Phases
Phase 3: Arthritis, Juvenile|Arthritis, Psoriatic|Arthritis, Rheumatoid|Bursitis|Colitis, Ulcerative|Dupuytren Contracture|Psoriasis|Spondylitis, Ankylosing|Uveitis, Anterior
Phase 1: Arthritis, Infectious|Behcet Syndrome|COVID-19|Crohn Disease|Healthy Volunteers|Hidradenitis Suppurativa|Spondyloarthritis|Uveitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| KnaPsAck | P3 |
Recruiting |
Arthritis, Psoriatic|Arthritis, Juvenile |
2026-09-01 |
|
| CRI-RA | P3 |
Recruiting |
Arthritis, Rheumatoid |
2025-12-01 |
|
| M10-870 | P3 |
Unknown Status |
Colitis, Ulcerative |
2025-05-14 |
|
| S67402 | P3 |
Unknown Status |
Dupuytren Contracture |
2025-03-18 |